Natera is a rapidly growing genetic testing and diagnostics company with proprietary bioinformatics and molecular technology. Natera’s team of PhDs and engineers is dedicated to refining novel molecular genome assays and complex statistical algorithms to determine the likelihood of a wide range of serious genetic conditions with best-in-class accuracy and coverage. Natera’s goal is to change the management of genetic disease worldwide, giving patients and providers essential health information.
Natera was founded in 2004.
As of December 31, 2021, Natera had 2,670 employees.
Natera went public on July 1, 2015 at $18.00 per share.
Our underwriters were Morgan Stanley & Co. LLC, Cowen and Company, LLC, Piper Jaffray & Co., Robert W. Baird & Co. Incorporated, and Wedbush Securities Inc.
All of Natera’s financial publications are available here.
Natera is listed on the Nasdaq Global Select Market under the ticker symbol NTRA.
The current and historical stock price of NTRA can be found here. For more current information and historical prices, visit our Stock Information pages.
Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021(800) 662-7232
The CUSIP number for Natera’s common stock is 632307104.
Natera has never declared or paid any cash dividend on its capital stock and does not anticipate paying any dividends in the foreseeable future.
Natera’s fiscal year ends December 31.
Ernst & Young LLP.
Please visit our Contact page.